[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100654988":3},{"organization":4,"outcomesModule":7,"designInfo":13,"detailedDescription":11,"studyPopulation":11,"armGroups":19,"interventions":26,"overallOfficials":33,"centralContacts":37,"locations":43,"responsibleParty":111,"collaborators":11,"id":113,"slug":114,"hasResults":115,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":115,"sex":121,"minAge":122,"maxAge":11,"enrollmentInfo":123,"targetDuration":11,"studyType":126,"phases":127,"briefSummary":129,"conditions":130,"keywords":11,"overallStatus":132,"whyStopped":11,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":142},{"fullName":5,"class":6},"Annexon, Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Number of Participants with Treatment Emergent Adverse Events",null,"Through Month 24",{"allocation":14,"interventionModel":15,"interventionModelDescription":11,"primaryPurpose":16,"observationalModel":11,"timePerspective":11,"maskingInfo":17},"NA","SINGLE_GROUP","TREATMENT",{"masking":18,"maskingDescription":11,"whoMasked":11},"NONE",[20],{"label":21,"type":22,"description":23,"interventionNames":24},"Vonaprument","EXPERIMENTAL","Participants will receive vonaprument IVT injections every month for 24 months.",[25],"Drug: Vonaprument",[27],{"type":28,"name":21,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","Form: solution for injection; Route of Administration: IVT injection",[21],[32],"ANX007",[34],{"name":35,"affiliation":5,"role":36},"Clinical Trials","STUDY_DIRECTOR",[38],{"name":39,"role":40,"phone":41,"phoneExt":11,"email":42},"Study Coordinator","CONTACT","650-822-5500","clinicaltrials@annexonbio.com",[44,57,66,76,81,91,101],{"facility":45,"status":11,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":11},"Retina Group of Florida","Sarasota","Florida","34233","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-82.53065,27.33643,{"lat":55,"lon":54},{"facility":58,"status":11,"city":59,"state":47,"zip":60,"country":49,"countryCode":50,"cosmosGeoPoint":61,"geoPoint":65,"contacts":11},"Retina Vitreous Associates of Florida","St. Petersburg","33711",{"type":52,"coordinates":62},[63,64],-82.67927,27.77086,{"lat":64,"lon":63},{"facility":67,"status":11,"city":68,"state":69,"zip":70,"country":49,"countryCode":50,"cosmosGeoPoint":71,"geoPoint":75,"contacts":11},"Cumberland Valley Retina Consultants","Hagerstown","Maryland","21740",{"type":52,"coordinates":72},[73,74],-77.71999,39.64176,{"lat":74,"lon":73},{"facility":77,"status":11,"city":68,"state":69,"zip":70,"country":49,"countryCode":50,"cosmosGeoPoint":78,"geoPoint":80,"contacts":11},"Mid Atlantic Retina Specialists",{"type":52,"coordinates":79},[73,74],{"lat":74,"lon":73},{"facility":82,"status":11,"city":83,"state":84,"zip":85,"country":49,"countryCode":50,"cosmosGeoPoint":86,"geoPoint":90,"contacts":11},"Retina Research Institute at New England Retina Consultants","Springfield","Massachusetts","01107",{"type":52,"coordinates":87},[88,89],-72.58981,42.10148,{"lat":89,"lon":88},{"facility":92,"status":11,"city":93,"state":94,"zip":95,"country":49,"countryCode":50,"cosmosGeoPoint":96,"geoPoint":100,"contacts":11},"Asheville Eye Associates - Retina Division","Asheville","North Carolina","28803",{"type":52,"coordinates":97},[98,99],-82.55402,35.60095,{"lat":99,"lon":98},{"facility":102,"status":11,"city":103,"state":104,"zip":105,"country":49,"countryCode":50,"cosmosGeoPoint":106,"geoPoint":110,"contacts":11},"Verum Research, LLC","Eugene","Oregon","97401",{"type":52,"coordinates":107},[108,109],-123.08675,44.05207,{"lat":109,"lon":108},{"type":112,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100654988","phase-3-an-open-label-extension-study-of-the-long-term-safety-of-vonaprument-anx007-in-participants-with-dry-age-related-macular-degeneration-amd-with-geographic-atrophy-ga-100654988",false,"NCT07807969","An Open-label Extension Study of the Long-Term Safety of Vonaprument (ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)","A Multicenter, Open-Label Extension Study of the Long-Term Safety of Vonaprument (ANX007) Administered by Intravitreal Injection in Participants With Dry Age-Related Macular Degeneration With Geographic Atrophy","AiiM OLE","Inclusion Criteria:\n\n* Participants with a diagnosis of dry AMD with GA who completed the Phase 3 ARCHER II study (NCT06510816) and who had not permanently ceased receiving the assigned masked treatment (IVT or Sham administration) at\u002Fbefore the ARCHER II Month 24 Visit.\n\nExclusion Criteria:\n\n* Any event or condition arising during the ARCHER II study that would put the participant in danger or lead to undue harm by participating in this OLE study.","ALL","50 Years",{"count":124,"type":125},605,"ESTIMATED","INTERVENTIONAL",[128],"PHASE3","The primary purpose of the study is to assess the long term safety of intravitreal (IVT) injections of vonaprument.",[131],"Geographic Atrophy","NOT_YET_RECRUITING","2026-09-03",{"date":135,"type":136},"2026-09-08","ACTUAL",{"date":138,"type":125},"2026-09-30",{"date":140,"type":125},"2029-07-31",{"name":5,"class":6},7]